Archives: BioMedWire

August 13, 2021 13:38:54

Cannabis is now legal for recreational use in 18 states and legal for medicinal use in 36 states across the country. As the plant gains more popularity, so do some of its products, the most popular ones being THC and CBD, which are cannabinoids.

Cannabinoids are compounds found in the cannabis plant. Other cannabinoids found in the cannabis plant include tetrahydrocannabivarin (“THCV”), cannabinol (“CBN”) and cannabigerol (“CBG”), among others. These rare cannabinoids don’t possess THC’s psychoactive properties and have been found to be more potent in comparison to CBD. Forecasts show that by the year 2029, the international…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – RYAH Group Inc.’s (CSE: RYAH) State-of-the-Art IoT Products Provide Holistic View for Optimal Research

August 13, 2021 13:36:07

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is standing by to provide a wealth of smart devices, artificial intelligence and an integrated platform that will fully support the U.S. as it explores the benefits, risks and effects of cannabis. “U.S. researchers can benefit from RYAH Group’s state-of-the-art IoT suite of products. The technology collects, analyzes and leverages objective data throughout the research process. As a result, the company boasts one of the largest plant-based medicine databases globally with 200,000 plus registered users. The company’s ecosystem of products allows data to be collected from seed to consumption, providing a holistic view of the plant necessary for optimal research,” reads a recent article. “One of the major challenges for researchers is regulating dose size because cannabis is a chemically variable plant. RYAH Group specializes in precision dose control technology that helps to control this variable in a clinical setting.”

To view the full article, visit https://ibn.fm/wrNAz

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patient and demographics. With a strong intellectual property portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2021 Financial Results, Provides Business Outlook

August 13, 2021 09:15:46

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today reported its financial results for the quarter ended June 30, 2021. The company also provided a clinical update of its anti-cancer drug candidates currently in development for the treatment of primary and metastatic brain and CNS cancer. “Over the course of the second quarter, our team continued to execute on corporate, clinical and regulatory strategies to drive our Berubicin program toward regulatory approval as fast as possible. We are guided by our passion to answer one of the most devastating unmet clinical needs in medicine: unbelievably, patients suffering today from recurrent GBM still cannot turn to a single approved treatment anywhere in the world for hope. Simply put, this must change, and we are the company to change it. With the FDA’s recent award of Fast Track Designation for our lead program, we believe we are poised to finally bring a desperately needed treatment to GBM patients potentially through this accelerated pathway. Building on a foundation of sixty years of successful anthracycline use against numerous deadly cancers as well as powerful data from our phase 1 study of Berubicin, the only anthracycline which appears to cross the blood brain barrier in adults, we wholeheartedly believe in its potential to transform the current treatment landscape and the lives of patients,” said John Climaco, CEO of CNS Pharmaceuticals. “After a quarter of amazing progress, we are well positioned for even more significant advancements of our development programs, which we expect will continue to drive shareholder value in the near and long term.”

To view the full press release, visit https://ibn.fm/kZREh

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q2 2021 Financial, Operational Report

August 13, 2021 08:51:53

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced its most recent financial report, along with operational highlights for the second quarter, the period ended June 20, 2021. In part, the report noted that second-quarter revenue totaled $4.5 million, an increase of more than 37% year over year, and 30% over the first quarter 2021; revenue for the first half of 2021 totaled $7.9 million. Gross profit for second quarter was $3.6 million with gross margin 81% for the second quarter, both increases over the same quarter the previous year. The report also noted cash and cash equivalents for the company were $34.2 million. Business highlights included 19,000 total patients being treated with the Vivos system; the appointment of Mimi Guarneri, MD, FACC, as an independent consultant serving as medical director of clinical education; and Vivos founder and chief medical officer Dr. G. Dave Singh, DMD, PhD, DDSc, publishing a book, titled “Pneumopedics and Craniofacial Epigenetics,” to help doctors and dentists better address underlying craniofacial conditions that affect a patient’s overall airway, breathing and sleep health. “There are a number of key positive takeaways from our second quarter results,” said Vivos chair and CEO R. Kirk Huntsman in the press release. “First, we achieved strong revenue results ahead of our internal forecasts and analysts’ estimates, although the year-over-year comparisons are somewhat augmented due to the impact of COVID last year. Second, we have continued to focus on strategic sales and marketing initiatives, designed to introduce more healthcare and dental professionals to the benefits of the Vivos System. . . . Third, in addition to our core business of enrolling new VIPs and increasing sales of appliances, we have begun to see revenue from other sources we have implemented, including from our recently launched MyoCorrect orofacial myofunctional therapy service and the beginnings of management fee revenue from our Medical Integration Division as well as some revenue from VivoScore, which we view principally as a marketing tool. . . . Fourth, we have recently begun an active outreach to the DSO industry. DSOs, or Dental Support Organizations, own and operate thousands of dental practices throughout the U.S. and Canada.”

To view the full press release, visit https://ibn.fm/xhzyT

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective for more than 19,000 patients worldwide by more than 1,250 dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Bolsters its Advisory Board With The Appointment of Jerry White

August 13, 2021 08:00:01

Mind Cure Health Inc. announced Jerry White’s appointment into the company’s advisory board
Mr. White brings a wealth of experience from his years of powering global movements and working with key leaders and personalities around the world
MINDCURE forecasts that with Mr. White’s addition to the board, the company will be well-positioned to achieve bigger and better goals, all while working towards its overall vision of building mental wealth globally

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) announced that it has appointed Jerry White as an advisor to the company. Mr. White would be an excellent addition to the company’s advisory board given his expertise, ambition, and track record of the achievements (https://ibn.fm/Fnt3f). In an official statement confirming the appointment, Mr. White reckoned… Read More>> NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Bringing Groundbreaking Tech to Push Boundaries in Neurology Space

August 12, 2021

August 12, 2021 12:12:20

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears poised for rapid growth as the application space for EEG-based solutions expands. “With its current and future products, including disposable EEG headsets for neurological patients, long-term monitoring solutions, and AI-empowered technology for recording brain activity, the company appears well-placed within the growing brain monitoring space,” reads a recent article. This comes as the brain-computer interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. It is a promising approach to overcoming paralysis by decoding brain signals directly from the scalp and translating them into movements of a virtual or robotic effector. This powerful technology can provide opportunities for motor rehabilitation from a number of conditions and even help patients who’ve lost the ability to speak. “Committed to pushing the boundaries of what’s possible in the neurology space, Brain Scientific brings the groundbreaking technology that aims to enable what was inconceivable until recently.”

To view the full article, visit https://ibn.fm/oiwdT

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Anpac Bio Continues Growth Trajectory

August 12, 2021

August 12, 2021 10:35:18

In recent years, advances in technology have led to demand for early cancer testing and screening methods that are less invasive and lower cost. Insurance companies have accepted that traditional testing methods are labor intensive and are not ideal as the first line of defense when screening and diagnosing cancer. This has opened a multi-billion-dollar market opportunity in discovering new solutions to tackle cancer and disease testing outside of traditional diagnostics that have been used for generations without any major upgrades or breakthroughs. AnPac Bio-Medical Science Co., Ltd. (ANPC.US), a biotechnology company focused on early cancer screening and detection as well as cancer treatment, has established itself in China as a leader in disease screening and diagnosis, as well as having a team and bio-medical lab in the US, as the industry undergoes this transitional shift. It has championed a groundbreaking idea and technology called multi-(pan) cancer screening technology since 2010, and developed and announced multi-cancer screening technology in 2014, much earlier than most of is peers. It has developed a highly innovative cancer screening technology called Cancer Differentiation Analysis technology (CDA).

Taking advantage of this new paradigm, AnPac Bio finished with strong revenues in 2020, up 89.3% year-over-year, despite the global pandemic. Companies like New Horizon Health, listed in Hong Kong (6606.HK), achieved revenue growth of 20.0% in 2020 versus the prior fiscal year, and Genetron Health (NASDAQ: GTH), achieved revenue growth of…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Third-Party Content

The BMW website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the BMW Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of BMW or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and BMW does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by BMW providing you with this internet portal that makes accessible to you the ability to view third party content through the BMW site, BMW does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. BMW expressly disclaims liability relating to such third-party content. BMW and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, BMW reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.biomedwire.com/disclaimer.

Fluorescent Imaging Agent May Allow for Better Cervical Cancer Detection

August 12, 2021

August 12, 2021 09:51:02

Recently conducted research has discovered that cervical cancer can be detected by clinicians using a handheld microscope and a topical fluorescent imaging agent dubbed PARPi-FL. This imaging technique targets the PARP1 enzyme, which is overexpressed in this type of cancer. It has the potential to revolutionize cervical cancer biopsies and screenings.

Cervical cancer is the fourth most common cancer in women. Data shows that in 2018, nearly 600,000 women were diagnosed with this cancer type globally, with roughly…

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Why AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

August 11, 2021

August 11, 2021 13:17:56

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is focused on early cancer screening and detection. With an aim of changing the way people approach cancer screening, the company develops, distributes and deploys accessible early disease detection devices. “AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance,” reads a recent article discussing the company. “Cancer Differentiation Analysis (‘CDA’) is AnPac Bio-Medical’s approach to detecting cancer and pre-cancerous diseases. CDA uses the natural biophysical properties of blood and cellular proteins to discover cancerous environments before the tumors even form. CDA technology combines an assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead-up to serious health conditions and cancer. It is also used to pinpoint where cancer is most likely located and predict where the risk is highest in the future — all through a standard blood test, at a competitive price point.” To view the full article, visit https://ibn.fm/m20YK About AnPac Bio-Medical Science Co. Ltd. AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Adjournment of Special Meeting of Stockholders

August 11, 2021

August 11, 2021 10:59:35

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has adjourned its Special Meeting of Stockholders. The meeting was convened on Aug. 10, 2021, at 3 p.m. CT, and then adjourned, with a plan to reconvene on Aug. 17, 2021, at 3 p.m. CT. The reason for the adjournment was to solicit more votes on a key proposal. According to the announcement, the proposal in questions calls for approval of an amendment to the company’s certificate of incorporation to increase the number of authorized shares of company common stock to 200 million; the current number of authorized shares of common stock is 100 million. During the meeting, stockholders voted and approved several other proposals, including an amendment to the Amended and Restated 2012 Stock Incentive Plan, the issuance of additional shares of common stock of the company based on a previously approved equity line of credit arrangement; and the ratification of the appointment of Baker Tilly US LLP as POAI’s independent registered public accounting firm for the fiscal year ending December 31, 2021. Before the next scheduled meeting, POAI will solicit proxies from its stockholders. POAI is also encouraging all stockholders who have not yet voted to do so as soon as possible.

To view the full press release, visit https://ibn.fm/Fw6RW

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA (“DNA/RNA”) and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood and irrigation fluid, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Fingerprints May Facilitate Neurological Disease Detection

August 11, 2021

August 11, 2021 09:32:59

A scientist at EPFL (the Swiss Federal Institute for Technology) has discovered that it is possible to detect declining cognitive function by using the fingerprints of an individual’s brain. Brain fingerprints refer to the neural connections’ map as detected by brain imaging techniques.

The scientist stumbled upon this discovery after noticing that the brain fingerprints in individuals suffering from cognitive decline are more difficult to detect compared…

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific Inc. (BRSF) Addresses Critical Neurologist Shortfall with Cost-Effective, Portable Brain Diagnostic Devices

August 10, 2021

August 10, 2021 11:54:19

American Academy of Neurology warns of critical neurologist shortfall amid increased incidence of brain disorders
Brain Scientific addresses issue with portable, cost-effective brain diagnostic solutions that record EEGs in nearly any setting
Product development includes creation of AI and ML algorithms to detect seizures, dementia and other brain-related conditions
NeuroCap and NeuroEEG device patents approved in U.S., Europe and China

With a goal of addressing the current acute neurologist shortfall in the United States (https://ibn.fm/DrxvC), Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, has developed cost-effective and portable proprietary medical devices that are positioned to disrupt the electroencephalogram (“EEG”) market. According to a report from the American Academy of Neurology 2019 Transforming Leaders Program, nearly every U.S. state is experiencing a neurologist shortfall amid an increase in neurological disorders (https://ibn.fm/DrxvC). Experts warn that access to high-level care and diagnosis is immediately required to… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Scientists Can Use Blood Plasma, Urine Tests to Detect Brain Tumors

August 10, 2021

August 10, 2021 11:39:54

Scientists from the Cancer Research UK Cambridge Institute have designed tests that can detect the presence of a type of brain tumor known as a glioma via a patient’s blood plasma or urine. The group notes that this test is the first of its kind globally, adding that its results, which only included a handful of patients, are promising. The research is currently in its early stages and was published in “EMBO Molecular Medicine.”

Brain tumor recurrence in individuals who have already had a brain tumor removed is high, which is why monitoring patients using an MRI scan is important. Often, physicians also conduct…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Names Digital Therapy Visionary as Tech Advisor

August 10, 2021

August 10, 2021 09:02:19

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that Dr. Ken Weingardt, CEO of Audacious Digital Health, will be serving as senior clinical technology advisor. Weingardt is a clinical psychologist and has served as senior clinical director at Pear Therapeutics. Specifically, Weingardt will work with MINDCURE’s iSTRYM, the company’s digital therapeutics technology (“DTx”) platform, through near-term commercial deployment. iSTRYM is on schedule for MVP deployment in the third quarter of 2021, with commercial deployment slated for first quarter 2022. Weingardt , who most recently served as the director of clinical programs at Woebot Health, has two decades of experience focused on technology and behavioral health. iSTRYM is MINDCURE’s proprietary, first-of-its-kind software application that optimizes the healing journey for both patients and clinicians before, during, and after therapy sessions. The platform offers therapists global, evidence-backed treatment protocols, as well as in-session psychedelic-informed tools. In addition, the application features customizable dashboards, integration plans, insights into patient journeys and real-time assessments for personalized client care.

“Adding Ken to our team is a hallmark moment,” said MINDCURE president and CEO Kelsey Ramsden in the press release. “We are in the early days of this fast-growing psychedelics market and are proud that Ken chose to work with MINDCURE. I’m honored and excited to show what we will achieve together. I believe that vision, teamwork, and speed of execution are the keys of every disruptive business that delivers on its strategy and drives results for its customers and its investors.”

To view the full press release, visit https://ibn.fm/gpt4m

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific Inc. (BRSF) Positioned to Disrupt EEG Market with Cost-Effective Brain Imaging Devices

August 9, 2021

August 9, 2021 13:53:53

Brain Scientific poised to disrupt neurology market with two new FDA-cleared patented products that provide cost-effective brain imaging in any setting
Current global market for EEG devices estimated at $956.1 million with CAGR of 8.7% from 2019 to 2026, expected to reach $1.6 billion by 2026

With a focus on developing innovative and proprietary medical devices and software, Brain Scientific (OTCQB: BRSF), a commercial-stage health care company, is fulfilling its mission of modernizing and increasing accessibility to brain diagnostics with two new FDA-cleared products that provide next-generation solutions to the neurology market. Already patented in the United States, China and Europe, the company’s first commercialized devices — the NeuroCap(TM) and NeuroEEG(TM) — are designed to disrupt the current electroencephalogram… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

How to Make Remote Healthcare Better for Everyone as Implementation Spreads

August 9, 2021

August 9, 2021 13:01:51

Even before the coronavirus pandemic began, remote healthcare was on the rise. Remote healthcare, which is fast becoming the preferred way to deliver healthcare, has many benefits including reducing costs and freeing up healthcare facilities for critical needs.

It also provides more meaningful and robust data. Many view remote healthcare as more effective and efficient at tracking the health of. . .

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Positioned to be at Center Stage of Neurological Diagnostics Space

August 6, 2021 13:22:01

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, appears well-positioned to offer solutions for the growing market need in the post-pandemic world. “As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting,” reads a recent article. As such, the market for BRSF’s innovative products appears to expand. “It is becoming increasingly clear that neurological diagnostics will be at the center of the future post-COVID-19 health care of patients who suffered from the infection. As a commercial stage health care company focused on developing innovative medical devices and software disrupting the brain diagnostics market, Brain Scientific is poised to be at the center stage of neurological diagnostics space offering solutions for this growing public health problem with its two commercialized and FDA-cleared devices, NeuroCap(TM) and NeuroEEG(TM).”

To view the full article, visit https://ibn.fm/YTiKW

About Brain Scientific Inc.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Paving Way for Better Outcomes of Plant-Based Treatments

August 6, 2021 12:46:37

RYAH Group (CSE: RYAH), a connected device and big data and technology company, is known for its high-quality information and digital health care analytics through which it is positively impacting the future treatment of patients for various medical conditions worldwide. RYAH is partnering with the University of Milan and companies like Medical Kiwi to drive innovation and deliver cutting-edge medical solutions, as well as providing the necessary dose-measuring devices to an oncology clinic in the U.K. “RYAH Group is paving the way for a better understanding and better outcomes of plant-based treatments globally,” reads a recent article. “This is achieved by having multiple touchpoints and working with multiple players throughout the plant’s lifecycle. The company has partnered with growers, dispensaries, clinical trials, researchers, and patients to collect seed-to-consumption data. This creates a deeper understanding of the roles of formulations and dosing in treatments. . . [RYAH] has the necessary IoT devices needed to ensure these future studies collect and analyze the data in the most effective way possible.”

To view the full article, visit https://ibn.fm/kInPI

About RYAH Group Inc.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

New Model Could Result in More Customized Bladder Cancer Treatments

August 6, 2021 12:43:18

Researchers from the Uppsala University have developed a new mouse model that can be used to study the factors that contribute to the progression of immune-system activation and bladder cancer in humans as the tumor grows. Through this model, the researchers have learned how proteins change prior to, during and after tumor development in the bladder wall. Their findings were published in the “PLOS ONE” journal.

The study’s principal investigator Sara Mangsbo stated that the model was designed to demonstrate the harmful mutations observed in bladder cancer patients and to contain mutations that drive tumor growth, known as. . .

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Poised to Establish New Standard in Bladder Cancer Visualization

August 6, 2021 11:14:38

Imagin Medical (CSE: IME) (OTCQB: IMEXF) has developed the i/Blue Imaging System(TM), an innovative technology designed to significantly improve the way surgeons visualize cancerous cells for more accurate bladder resection. The patented technology, which has entered the manufacturing stage and is expected to be completed in 2022, allows for white and blue light images to be projected side-by-side simultaneously, enabling better surgical technique. It will also attach to most endoscopes currently on the market, protecting hospitals’ investment in instruments they already own and enabling their adoption of blue light cystoscopy at significant cost savings. A recent article reads, “With the i/Blue Imaging System, Imagin Medical is poised to establish a new standard in bladder visualization by radically changing how cystoscopies are performed and ultimately helping improve patient’s lives and long-term outlook.”

To view the full article, visit https://ibn.fm/dGXZH

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue Imaging System(TM), with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Testing Volume Increase for First Half of 2021

August 6, 2021 09:53:19

Total number of paid tests and paid cancer tests increased significantly in Q2 over Q1
The company’s approach to multi-cancer screening is called Cancer Differentiation Analysis (“CDA”) that is powered by a database of over 200,000 samples and cases, changing the way to approach disease and cancer screenings
The global cancer diagnostics market size is expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on early cancer screening, detection, and cancer treatment, announced that it experienced strong growth in test volume in the first half of 2021. The total number of paid customers and testing volume increased almost 110% compared to the same period in 2020. Additionally, Q2 saw the total of paid tests and paid cancer tests increase by approximately 280% and 270%, respectively. The company has also seen growth in the new test products that it had launched in 2020 (https://ibn.fm/Josef). AnPac is a highly innovative company and an early thought leader, developing multi-cancer screening technology, which has gained significant acceptance. The company’s approach, Cancer Differentiation Analysis… Read More>> NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Neuron Activation Timing Could Change Treatment for Brain Conditions

August 5, 2021

August 5, 2021 14:04:34

Research recently published in the “Cell” journal shows the existence of a neural code known as phase precession in the human brain. Phase precession refers to a neurophysiological process in which neurons signal information by changing the timing in which they activate. This timing code has been observed in rodents navigating through spaces, with researchers theorizing that it may form the basis for how the brain represents sequences.

This is the first time phase precession has been observed in humans. The study was conducted by Dr. Itzhak Fried, a neurosurgery professor at the UCLA David Geffen School of Medicine, in collaboration with associate professor of biomedical…

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific Inc.’s (BRSF) Rapid Response EEG Devices Provide Cost-Effective Solution for Neurology Market

August 5, 2021

August 5, 2021 13:10:17

Patented NeuroCap(TM) and NeuroEEG(TM) devices can be used anywhere, ideal for clinical research labs, neurology clinics, urgent care clinics, emergency departments, ICUs, assisted living facilities, and nursing homes
Current global market for EEG devices estimated at $956.1 million in 2020, expected to reach $1.6 billion revenue by 2026, CAGR of 8.7% between 2019-2026

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company, focuses on developing cost-effective next-generation medical devices and software with the goal of modernizing and increasing accessibility to brain diagnostics for the rapidly growing neurology market. Brain Scientific’s patented NeuroCap(TM) and NeuroEEG(TM) devices are positioned to disrupt the expensive EEG market. Company’s Neurotech ecosystem consists of devices that are affordable and sustainable FDA cleared alternatives to the EEG technology seen today. Devices can be used in a wide range of… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

AnPac Bio-Science Co., Ltd. Continues To Build On Its Success With What Many Thought Impossible – Multiple Cancer Screening

August 4, 2021

August 4, 2021 13:21:23

Summary

After ten years of hard work, the pan-cancer screening concept and efforts led by AnPac Bio-Science Co., Ltd. (“AnPac Bio”; NASDAQ: ANPC) since 2010 is gaining market acceptance and traction. AnPac Bio’s cancer screening technology uses sensors fabricated by integrated circuit (IC) process to detect multiple cancers in the blood at the same time. According to US marketing research firm Frost-Sullivan, AnPac Bio ranked top three globally in terms of clinical and commercial test sample numbers in the space of new cancer detection technologies in 2019. In the next five years, AnPac Bio strives to become a global leader in early cancer screening, continuing to make meaningful contributions to the global cancer prevention cause.

Lead:

As early as 2010, AnPac Bio proposed a pan- (multiple) cancer screening theory and method to change the way science and medical professional perform cancer tests. The hope was to help cancer testing become cheaper, faster, earlier, and cover more cancer types in one test. Some of Anpac’s issued patents in the US and China dated original ideas as early as 2010s1-3, and clinical study data were collected and…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Third-Party Content

How Depression Impacts Men, Women Differently

August 4, 2021

August 4, 2021 10:45:21

Researchers have reported that women and men can experience depression differently, and while both genders may share many common symptoms and signs, understanding these differences may better help those who suffer from this condition. The Connors Center for Women’s Health and Gender Biology director of research Jill Goldstein states that understanding the sex differences when it comes to depression is essential because it helps understand the condition better.

Goldstein notes that among the most significant differences between the genders when it comes to depression is the fact that women are twice as likely to develop the condition in comparison with men. Goldstein explains that this is, in part, based on biological reasons, such as genes and hormones getting disrupted when regions in the brain are developing in the female and male fetus. These biological changes occurring as a fetus develops are what create…

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Names Nobel Peace Prize Recipient as Company Advisor

August 4, 2021

August 4, 2021 08:51:17

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has appointed Jerry White as a company advisor. A passionate activist, author and social entrepreneur, White is the recipient of numerous human rights and leadership awards, including sharing the Nobel Peace Prize in 1997. In his new role, White will advise MINDCURE on its mission to revolutionize mental health treatments worldwide through the development and scaling of science-backed psychedelic medicine. White shares in the 1997 Nobel Prize for Peace, which was awarded to the International Campaign to Ban Landmines, an organization that he leads. White is a senior Ashoka Fellow and has worked alongside the late Diana, Princess of Wales, and Her Majesty Queen Noor of Jordan. He was also appointed U.S. Deputy Assistant Secretary of State by President Barack Obama. When he was 20, he lost a leg to a landmine while hiking in northern Israel and consequently co-founded Survivor Corps, an organization created by and for survivors to help victims of war rebuild their lives. He is currently a professor of practice at the University of Virginia, where he teaches on religion, violence and strategy. White noted that his own experience learning to build resilience for trauma recovery, as well as engaging large audiences to power global movements, would help MINDCURE and the psychedelics industry advance revolutionary wellness worldwide. “Never shying away from audacious goals, driving transformational global movements, asking the toughest of questions, and translating them to strategy — this is what Jerry brings and why I am so thrilled to welcome him to the advisory board at MINDCURE,” said MINDCURE president and CEO Kelsey Ramsden in the press release. “It’s an honor to welcome a truly noble and humane impact strategist to our advisory board. I look forward to working with Jerry on our visionary strategy to build mental wealth worldwide.”

To view the full press release, visit https://ibn.fm/5gnYS

About Mind Cure Health Inc.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

New Evidence Links Fibromyalgia to Immune System

August 3, 2021

August 3, 2021 14:24:28

A team of researchers from the Karolinska Institutet in Stockholm, the University of Liverpool and King’s College London has found that many symptoms of fibromyalgia occur when the antibodies in an individual increase the activity of pain-sensing nerves.

Fibromyalgia is a chronic syndrome that causes mental distress and bodily pain. The disease is classified as a rheumatic condition because it causes myofascial pain or soft tissue pain. Individuals living with fibromyalgia also have sensitivity to cold and pressure all over their bodies, in addition to experiencing emotional distress, fatigue and trouble sleeping. It is estimated that roughly 4 million adults in the United States are living with fibromyalgia, with trusted…

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured on The Dealmaker Show, to Present at Canaccord Genuity Annual Growth Conference

August 3, 2021

August 3, 2021 12:28:12

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was featured on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff. Tryp’s CEO and Chairman Greg McKee joined the latest episode to discuss the company’s focus on psychedelics, how he got involved with Tryp and what opportunities the company sees in the psychedelics space. “It’s really simple. There are a lot of naturally derived chemistries around that eventually find their way into more traditional drug development pathways. Psychedelics are some of those,” McKee said. “These chemistries have been around since the 1960s and ‘70s. We know they are well tolerated. Since then, several respected academics at NYU, Johns Hopkins, Yale University and others have been studying these compounds.”

In addition, Tryp Therapeutics today announced that it will present at the Canaccord Genuity Virtual Growth Conference. The event is slated to take place virtually on Aug, 10-12, 2021. Beginning at 3:00 p.m. ET on Aug. 10, McKee will provide an overview of the business and its pipeline, including Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program for chronic pain and eating disorder indications. Interested parties should visit https://ibn.fm/uWnDZ to register.

To view the full press releases, visit https://ibn.fm/GbhCC and https://ibn.fm/8z2Qe

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders PFN(TM) (“PFN”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain chronic pain and eating disorder indications. The company has announced upcoming phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and method of delivery to improve the patient experience. For more information about the company, visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Is ‘One to Watch’

August 2, 2021

August 2, 2021 12:33:26

AnPac Bio-Medical Science Co. Ltd. is a biotechnology company focused on early cancer screening and detection
The company aims to develop, distribute and deploy its Cancer Differentiation Analysis (“CDA”) technology to change the way people approach cancer screening
CDA is powered by a database of over 200,000 samples and cases, providing a new way to approach disease and cancer screening
The company’s management team comprises professionals in both the United States and China who are knowledgeable and well educated in cancer screening and detection
The global cancer diagnostics market is expected to reach $249.6 billion by 2026

AnPac Bio-Medical Science Co. (NASDAQ: ANPC) is a biotechnology company focused on early cancer screening and detection. The company develops, distributes and deploys accessible early disease detection devices with an aim of changing the way people approach cancer screening. AnPac Bio-Medical is a highly innovative company and an early thought leader and developer of multi-cancer screening technology, which is gaining significant acceptance. AnPac Bio-Medical has clinical laboratories in the United States and China, with 142 issued patents as of March 31, 2021. Its corporate headquarters is located in Shanghai, China, while its U.S. headquarters is… Read More>> NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Study Finds Extensive Variations in Cost, Transparency of Thyroid Cancer Care

August 2, 2021

August 2, 2021 11:29:53

A mandate from the Centers for Medicare and Medicaid Services directed that from Jan. 1, 2021, all hospitals in the United States provide pricing information online about their services and items. The objective of this mandate is to help inform patients about the cost of procedures and services before they receive them.

Researchers from Brigham and Women’s Hospital and Massachusetts Eye and Ear used this data to examine price variation and transparency for thyroid cancer treatment. They discovered that both price and transparency differed greatly, with the costs of various…

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Launches Second Stage of Manufacturing of Ibogaine for Clinical Research

July 30, 2021 11:09:12

The company has filed patent applications for two routes of chemical synthesis of ibogaine – offering potential advantages of improved isomeric purity, chiral purity, and easily isolated intermediate compounds
Preliminary data indicates that the drug shows promise as a treatment for neuropathic pain and migraines, as well as the treatment of addiction
The company is positioned to engage several markets, including digital therapeutics and research

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”), a diversified life sciences company at the forefront of the mental health industry, recently announced the launch of its second manufacturing stage of pharmaceutical-grade ibogaine to be used in psychedelic clinical research. During this stage of manufacturing, the company will be assessing the quality of the synthetic ibogaine to be produced at scale to determine the timing and cost for commercial-scale manufacturing (https://ibn.fm/xOXo9). Kelsey Ramsden, President and CEO of MINDCURE, spoke on the manufacturing goals stating, “We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research… Read More>> NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific Inc. (BRSF) Poised to Benefit as Rapidly Growing Brain-Computer Interface Field Drives EEG Growth

July 30, 2021 11:08:18

Brain-Computer Interface (“BCI”) market is expanding rapidly, expected to double to USD 406 billion by 2026
BCI technology, designed to acquire brain signals, analyze and translate them into commands, is one of key driving forces behind EEG technology growth
Brain Scientific appears poised to capitalize on this novel technology as its applications expand from medical settings to training, consumer engagement, entertainment, and more

The Brain-Computer Interface (“BCI”) field is growing rapidly, representing one of the main driving factors behind the expansion of EEG technology. As the provider of EEG technology, Brain Scientific (OTCQB: BRSF) appears well placed to leverage this rapid growth of the industry expected to double in size by 2026 (https://ibn.fm/F5LOs). BCI technology refers to solutions that record the brain signal from the surface of the cortex, using sensors placed over the scalp or signaling devices implanted in the brain. As a promising approach to overcome paralysis by decoding brain signals directly from the scalp and translating them into movements of… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Developing, Delivering New Generation of MedTech Solutions for Brain Diagnostics Market

July 30, 2021 11:05:13

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, recently announced its entry into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology. The merger is anticipated to expand the market footprint both for Brain Scientific and Piezo Motion, as well as the potential to deliver innovative technologies to high-growth sectors. Dr. Baruch Goldstein, founder of Brain Scientific, was quoted in a recent article as saying, “Together, we plan to achieve rapid expansion while delivering and developing the new generation of MedTech solutions for the brain diagnostics market, including innovative products for long-term monitoring and brain e-tattoo. This combination offers a significant opportunity to be part of a company well-positioned for growth.”

To view the full article, visit https://ibn.fm/PjMJG

About Brain Scientific Inc.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Biomarkers May Help to Accurately Predict ADHD Diagnosis

July 30, 2021 10:15:02

Research that was published in Frontiers in Physiology has found that communication among different regions in the brain, which is referred to as brain connectivity, could possibly serve as a biomarker for attention-deficit hyperactivity disorder (“ADHD”). For the study, researchers from the University of Buffalo in collaboration with the University of Cincinnati used machine-learning classifiers to identify grown-ups who had been diagnosed with ADHD during their childhood with 99% accuracy.

The researchers note that these findings may be useful in helping clinicians find proper treatments that address the specific needs for each patient and may also increase the ease with which this disorder is diagnosed. In a press release, Chris McNorgan, who was part of the study, stated that understanding the different ADHD types could assist clinicians in making decisions concerning the medications…

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Study Finds That Plant-Based Diets May Be Better for Heart Health

July 29, 2021

July 29, 2021 13:41:30

A recent study has discovered that diets rich in plant foods are better than low-fat diets when it comes to decreasing the risk of stroke and heart disease. The study monitored more than 5,000 Americans, with the scientists finding that individuals who ate diets low in saturated fat had lower LDL levels.

Saturated fat is known to increase LDL cholesterol levels and is mostly found in animal products. LDL cholesterol, or low-density lipoprotein, is considered a bad cholesterol as it contributes to fatty buildup in the arteries. However, the researchers note that lower LDL levels didn’t translate to a lower risk of stroke or heart disease. Contrastingly, individuals who consumed a lot of plant foods, including nuts, beans, whole grains, fruits and vegetables, did have lower risks…

NOTE TO INVESTORS: The latest news and updates relating to Healthy Extracts Inc. (OTCQB: HYEX) are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Proprietary Imaging System Set to Advance Bladder Cancer Visualization

July 29, 2021

July 29, 2021 12:48:19

Approximatively 75-85% of patients with confirmed cases of bladder cancer are diagnosed with non-muscle invasive (“NMIBC”)
Imagin Medical’s innovative technology is targeting this type of bladder cancer and set to be completed in 2022
Blue light cystoscopy helps surgeons visualize the cancerous cells that are not detected by white light, enabling an improved resection

Non-muscle-invasive bladder cancer (“NMIBC”) is a type of bladder cancer that has not infiltrated the other muscle tissues inside the bladder or spread to the lymph nodes. Approximately 75-85% of patients presenting with bladder cancer are diagnosed with NMIBC. The most common symptoms of NMIBC which may prompt initial testing is blood in the urine (https://ibn.fm/wO76R). The primary procedure used to detect bladder cancer is called a cystoscopy, which uses an endoscope and, typically, white light visualization. White light cystoscopy has been the standard for more than 90% of the procedures for decades and is beneficial in removing cancerous growths that protrude from the… Read More>> NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Opening of Denver-Based State-of-the-Art International Training Center

July 29, 2021

July 29, 2021 11:29:58

To view the full press release, visit https://ibn.fm/rAcJV

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 17,000 patients worldwide by more than 1,200 dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Is ‘One to Watch’

July 28, 2021 12:27:08

MINDCURE’s proprietary digital therapeutics technology platform creates a high barrier to entry for any potential competitors
The company maintains active partnerships with growing firms in AI, technology, and mental health
MINDCURE’s world-class scientific discovery team has decades of combined experience in researching and commercializing pharmaceutical grade drugs
The company has demonstrated a clear path to near-term revenues and boasts a strong financial position

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health. MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per… Read More>> NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Clear Opportunity to Bring Impactful Therapy to GBM Patients

July 28, 2021 11:11:29

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several milestones demonstrating its operational, financial and strategic strengths and continuous de-risking of its lead candidate Berubicin clinical program. “The company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma multiforme (‘GBM’). Enrollment in the clinical trial is already underway, with patient dosing set to begin in Q3 2021,” reports an article discussing the status of the study to treat GBM, an aggressive type of brain cancer with most treatments only slowing progression and reducing symptoms. “Berubicin is a novel therapy for GBM and the first anthracycline to cross the blood-brain barrier and kill cancerous tumor cells in humans. The Phase 1 safety trial for Berubicin was conducted by another company 14 years ago. Since then, one patient has lived cancer-free, with two others seeing a reduction in tumor size by up to 80%. . . . With the serious unmet medical need for new GBM treatments, CNS Pharmaceuticals applied for and was granted FDA Fast Track Designation for Berubicin. According to CNS Pharmaceuticals CEO John Climaco, receiving Fast Track Designation is a major achievement for the advancement of Berubicin for the treatment of the most aggressive, deadly and treatment-resistant type of brain cancer. ‘Patients have almost no meaningful options and thousands lose their fight against this terrible cancer every year. With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,’ he explained.”

To view the full article, visit https://ibn.fm/lsaX2

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates

July 28, 2021 09:46:05

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at home or at the point-of-care. “We believed in 3a’s research and development plan from the beginning, when we signed the first collaboration contract in 2020. Now that XPhyto has announced the pending acquisition of 3a, we are particularly excited about this development milestone,” said Wolfgang Probst, director and COO of XPhyto. “Successful validation of the first biosensor candidates demonstrates the expertise and scientific excellence at 3a. Since the co-developed and successfully approved German CE marked 25-minute PCR test in March of this year, this novel approach for oral biosensor screening is another important milestone towards development of tools to effectively identify infectious breakouts of COVID-19 to reduce the pandemic spread and help find our way back to the new normal.”

To view the full press release, visit https://ibn.fm/ZsKbh

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Discover New Phase in Stem Cell Cycle That May Help Develop Tumor Treatments

July 28, 2021 09:39:08

Researchers from Arizona State University are conducting a study on the life cycle of stem cells. The study may be useful in the development of new techniques for treating brain cancer. The research was reported in the “Molecular Systems Biology” journal.

Assistant professor of biomedical engineering from the institution’s school of engineering Christopher Plaisier stated that the research team had discovered a new phase in the cycle during their study. This new information was discovered through an alliance with associate professor Patrick Paddison from the Fred Hutchinson Cancer Research Center and University of Washington’s assistant professor of neurological…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs

July 27, 2021

July 27, 2021 14:46:26

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation solutions and stability services so the company can rapidly provide clinical-trial-ready formulations to its customers. The lab will also be utilized to produce proprietary media used in its chromatography kits. A recent article reads, “Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he expects the new GMP capabilities to ‘significantly increase the potential customer base and lead to multiple long-term collaborations.’” TumorGenesis will use its new lab to produce media as well, among other things. “According to Predictive Oncology Senior VP of Research and Development Richard Gabriel, the company scaling into GMP production of media means that it will be able to meet the needs of researchers.”

To view the full article, visit https://ibn.fm/lBjMu

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical, and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Danish Researchers Discover That Medical Marijuana May Combat Essential Tremor

July 27, 2021

July 27, 2021 12:42:09

There is huge debate on what medicinal properties, if any, marijuana possesses, and researchers are working to uncover the effects of this substance. For example, a team of researchers from the University of Copenhagen in Denmark has discovered that medical marijuana has the ability to reduce involuntary shaking or essential tremor. Their research used a mouse model.

The team’s work focused on a synthetic cannabinoid WIN55.212-2. The scientists found that when the mice were injected with this cannabinoid, astrocytes or support cells found within the brain and spinal cord of the mice were activated. When those support cells are activated, they trigger the release of adenosine, which has the effect…

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Manufacture of Synthetic Ibogaine Moves to Second Stage

July 27, 2021

July 27, 2021 10:44:43

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has begun the second stage of manufacturing pharmaceutical-grade ibogaine to be used in clinical research. According to the announcement, this stage will focus on assessing the quality of MINDCURE’s synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing. The company intends to manufacture pharmaceutical-grade ibogaine to provide researchers with a consistent supply of sustainable, high-quality, reliable psychedelic substance. The company has already filed patent applications for two routes of chemical synthesis of ibogaine, with both options showing potential to provide synthetic ibogaine with improved isomeric purity, increased purity and more easily isolated intermediate compounds; MINDCURE is in the process of assessing which method to develop further. The psychoactive substance ibogaine is found naturally in the roots of the iboga tree, which grows in Africa, and has been shown to influence pain, addiction and neurodegenerative conditions. In addition to providing outside researchers with a consistent supply of pharmaceutical-grade ibogaine, MINDCURE’s own research team will also use the drug in its development studies. “We are now one step closer towards our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes,” said Mind Cure Health president and CEO in the press release. “We are currently working on proving the ability to scale up the production, and our next step will be to test the ibogaine to ensure it meets the highest standards of pharmaceutical grade product.”

To view the full press release, visit https://ibn.fm/jDr7c

About Mind Cure Health Inc.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Avricore Health Inc.’s (TSX.V: AVCR) (OTCQB: AVCRF) HealthTab(TM) Adds ID Now(TM) Molecular Test Device to Abbott Distribution Agreement

July 26, 2021

July 26, 2021 09:37:28

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) today announced the signing of the first amendment to its supplier distribution agreement between HealthTab(TM) Inc., a wholly owned subsidiary, and Abbott, a global health care company and diagnostics leader in Canada. According to the update, the agreement, first signed on May 31, 2021, allows HealthTab(TM) to distribute in Canada Abbott’s Afinion(TM) 2, as well as associated tests for diabetes and heart-disease screening in community pharmacies. This includes HbA1c testing, which lead to the subsequent signing of a master agreement with Shoppers Drug Mart to bring this new testing to select locations as an initial pilot program. “A missing link today in the response to COVID-19 and general virus outbreak is the ability to get confirmatory testing and reliable, real-time reporting in a low-barrier setting,” said Hector Bremner, CEO of Avricore Health. “With ID Now(TM) on the HealthTab(TM) network in community pharmacy, patients can know what they have and get focused treatment and prevent spread through better information.”

To view the full press release, visit https://ibn.fm/Teb4m

About Avricore Health Inc.

Avricore Health is a pharmacy service innovator focused on acquiring and developing early stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab(TM) (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies. For more information about the company, visit www.AvricoreHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Post-Op Immunotherapy May Lower Risk of Bladder Cancer Recurrence

July 26, 2021

July 26, 2021 09:05:25

A new study conducted by researchers from the Memorial Sloan Kettering Cancer Center has discovered that after undergoing bladder removal operations, the risk of high-grade bladder cancer recurrence decreased after the nivolumab formulation was administered to patients.

Together with a group of researchers, Dr. Dean Bajorin, who is a medical oncologist at the institute, evaluated more than 700 patients who had a high risk of urothelial cancer recurring after their kidney, ureter or bladder had been removed because of advanced…

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers Compare COVID-19 to Other Respiratory Ailments

July 23, 2021

July 23, 2021 11:07:39

A group of researchers from the United States and Israel conducted a study that compared the disease progression and presentation between in-hospital patients suffering from COVID-19 with other respiratory ailments such as influenza. They discovered that coronavirus patients displayed a unique cardiorespiratory, immune and metabolic profile, noting that the disease’s severity was higher in comparison with other respiratory illnesses.

The virus that causes the coronavirus, SARS-CoV-2, is a deadly and highly infectious virus. It has infected more than 190 million individuals and claimed more than 4 million lives across the globe, despite the effective control measures that were implemented…

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Poised as Key Innovative Leader at Forefront in Neurology Tech

July 23, 2021

July 23, 2021 10:14:38

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is a recognized leading innovative player in the brain monitoring space. The company continues to be at the forefront of what is next in neurology technology. In a Tech Times feature, Brain Scientific’s Marketing Director Irina Nazarova outlined key brain monitoring trends to watch in 2021, including the fact that brain monitoring is becoming as popular and widespread as monitoring pulse or heart rate. Several potential applications have swelled, and EEG monitoring is no longer a preserve of clinicians and expert neuroscientific researchers. A recent article reads, “Exciting new opportunities are potentially in front of EEG technology. EEG-based products go beyond the medical space and are on their way to penetrate new sectors and find more uses. Brain Scientific is committed to remaining a key innovative leader in what could potentially be a rapidly growing market over the next years.”

To view the full article, visit https://ibn.fm/LojNW

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices, or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Looking to Unlock Additional Value with Russell 2000 Index Inclusion

July 23, 2021

July 23, 2021 10:00:48

CNS Pharmaceuticals (NASDAQ: CNSP), a pharmaceutical company enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of its lead drug candidate, was selected to be added to the Russell 2000 Index effective June 25. A subset of the Russell 3000 Index, the Russell 2000 Index is a measure of the performance of the small-cap segment of the U.S. equity market. Per CNS Pharmaceuticals CEO John Climaco, quoted in a recent article, the company was pleased to meet this noteworthy milestone. He said, “As our team continues to drive our clinical program forward for the treatment of glioblastoma multiforme (‘GBM’), we believe this inclusion well-positions us to drive market awareness. . . We look forward to leveraging the access and positioning this inclusion brings to unlock additional value.”

To view the full article, visit https://ibn.fm/2DOXO

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Study Finds That Focusing on the Past May Worsen Symptoms of Depression

July 22, 2021

July 22, 2021 11:21:25

A study recently published in the “Journal of Psychiatric Research” discovered that childhood trauma was linked to higher symptoms of depression, particularly in individuals who demonstrated a tendency to focus on the past instead of the future or even the present. Clinical depression, which is also known as major depressive disorder, is among the most common mental health conditions in the world. Childhood trauma is a typical feature of the disorder.

The authors of the stud — Yingying Wang and colleagues — suggest that a personality factor may play a role in this association between depression and early trauma, noting that an individual’s tendency to focus more on the past than the present as well as the future has been associated with both depressive symptomology and childhood trauma. The researchers sought to investigate whether focusing…

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Teasing About Weight Could Trigger Eating Disorders

July 21, 2021

July 21, 2021 13:36:29

Prior studies have discovered that young individuals who experience discrimination or teasing about their weight have higher rates of eating disorders, self-harm, depression and social isolation. However, these studies have primarily focused on high-income and white participants, which makes it unclear whether these findings apply to other groups as well.

This is why researchers from the School of Public Health at the University of Minnesota in Minneapolis conducted a study to examine the link between eating disorders and weight stigma in a socioeconomically and racially/ethnically diverse sample of more than 1,500 young…

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Begin Patient Dosing in Berubicin Phase 2 Clinical Trial During Q3 2021, and Received Fast Track Designation from FDA

July 21, 2021

July 21, 2021 10:48:50

CNS Pharmaceuticals has been granted FDA Fast Track Designation for Berubicin due to the serious unmet medical need for new GBM treatments
Enrollment into the potentially pivotal study for Berubicin and glioblastoma multiforme (“GBM”) in adults is already underway
CNS Pharmaceuticals also secures additional funding of $4.7 million for pivotal study and operations into Q2 2022, adding to company’s significant accomplishments in short time

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, achieved several fundamental clinical, corporate, and regulatory milestones over the last couple of months, demonstrating the company’s operational, financial, and strategic strengths and continuously de-risking its lead candidate Berubicin clinical program. According to a company press release providing critical operational updates, the company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma… Read More>> NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Adequate Levels of Vitamin D May Benefit Breast Cancer Patients

July 20, 2021

July 20, 2021 13:39:29

A new study has found that patients with breast cancer who have sufficient levels of vitamin D have better outcomes in the long term. Prof. Song Yao, who is the lead author of the study, suggests that maintaining adequate levels of vitamin D at the time of diagnosis and even after treatment may benefit breast cancer patients.

The study’s results, which were presented at the American Society of Clinical Oncology’s virtual annual meeting, included findings that show that Black women had the lowest levels of vitamin D, which may explain why they had poorer outcomes after…

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Definitive Agreement to Acquire 3a-Diagnostics

July 20, 2021

July 20, 2021 10:08:59

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, has signed a definitive agreement to acquire its exclusive diagnostics development partner 3a-diagnostics GmbH, Frickenhausen, Germany. Per the terms of the definitive agreement, XPhyto will acquire all outstanding shares of 3a for EUR 400,000, to be paid immediately, and EUR 3.5 million, to be paid on closing, which is anticipated to take place on or around October 31, 2021. This acquisition will create considerable commercial development and manufacturing opportunities for XPhyto, in addition to providing improved margins on its diagnostic products. “We have collaborated closely with the 3a-diagnostics team on several diagnostics products and have found them to be a highly innovative and focused partner. The successful development and recent launch of the 25-minute PCR test COVID-ID Lab is a great example of our fruitful collaboration. We strongly believe that this acquisition will result in powerful synergies and further feed XPhyto’s diagnostic pipeline, supporting our long-term commercial growth plans.” XPhyto Therapeutics CEO Hugh Rogers stated in the news release.

To view the full press release, visit https://ibn.fm/Qqzxu

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

An exclusive collaboration agreement between XPhyto and 3a-diagnostics, announced in April 2020 and amended in July 2020, paved the way for the development and commercialization of rapid, point-of-care, low-cost, and easy-to-use infectious disease screening tests which include COVID-19 diagnostics and oral dissolvable biosensors for pandemic threats and dental health applications. For more information, visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Study Finds Regular Physical Activity Boosts Brain Health in Growing Children

July 19, 2021

July 19, 2021 12:32:57

A recent study conducted by researchers from Boston Children’s Hospital has found that exercise assists in the organization of developing brains in growing children. The study discovered that physical activity was linked to more flexible, strong and efficiently organized brain networks.

Dr. Caterina Stamoulis, who is the study’s lead, conducted an analysis of brain imaging data collected from an estimated 6,000 children between the ages of nine and ten. Stamoulis, who is also the head of the Boston Children’s Computational Neuroscience Laboratory, explained that the physical activity children engaged in didn’t matter as long as they were active. She conducted the study with her trainees…

NOTE TO INVESTORS: The latest news and updates relating to Healthy Extracts Inc. (OTCQB: HYEX) are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Announces Successful Beta Testing of HealthTab(TM)

July 19, 2021

July 19, 2021 11:23:59

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) today announced that patient testing has begun on the first deployment of the new HealthTab(TM)-integrated Afinion 2(TM) analyzers in the initial Shoppers Drug Mart(R) pharmacy location. This move is part of the company’s previously announced effort to screen for diabetes and cardiovascular disease, demonstrating strong demand, smooth workflow and reliable system operations. To prepare for the full public launch, a first store was selected to receive the system to begin beta-testing HealthTab(TM)’s systems, including the first patient tests. HealthTab(TM) and the instruments are performing well, demonstrating that the first installation of HealthTab(TM) with the Afinion 2(TM) analyzers is ready for prime time. “I’m so excited to have HealthTab(TM) in my store because I believe this is going to demonstrate a new and better way to do pharmacy practice,” said Mohamed Adel Elsabakhawi, the first pharmacist and associate owner of a Shoppers Drug Mart located in Mississauga, Ontario, to operate the platform. “This is really profound because having access to lab-accurate results at our fingertips means we can better help family physicians by conducting regular follow up using advanced diagnostics with our diabetic and cardiovascular patients more effectively.”

To view the full press release, visit https://ibn.fm/6iCwu

About Avricore Health Inc.

NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

July 19, 2021

July 19, 2021 10:26:54

XPhyto partners with AGORA t to grow its brand and overall market share
The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021
AGORA is known for its online marketing, conferences, broadcasting and investor relations services
Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp (“AGORA”) that dates back to December 1, 2020.

The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 with respect to the various applicable securities legislation. With this move, AGORA now holds 20,549 common shares of…

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

New Research Finds Neurological Damage in Patients Hospitalized with COVID-19; Brain Scientific (BRSF) Appears Poised to Offer Technology That Can Help Understand How COVID-19 Affects Brain

July 16, 2021 13:52:00

Scientific evidence is mounting that SARS-CoV-2 can cause neurological damage in patients hospitalized with the infection.
A recent study that appeared in the journal JAMA Network Open finds five times increased mortality risk in patients hospitalized with COVID-19, citing encephalopathy as the most common neurological disease found in the clinical setting.
As more research is needed to understand how COVID-19 affects the brain, Brain Scientific appears poised to offer technology solutions as a leading player in the neurological diagnostics space.

As the world learns more about the novel SARS-CoV-2 virus, the evidence about neurological symptoms developed by patients who suffered from COVID-19 is mounting, and the market for Brain Scientific’s (OTCQB: BRSF) innovative products appears to expand. A recent article published in Medical News Today discusses findings of the observational study examining neurological issues in patients hospitalized with COVID-19. The research which appeared in the journal JAMA Network Open unveils that the most prevalent neurological symptom observed in the clinical setting was acute encephalopathy also finding a relationship between neurological issues and a higher risk of dying in the hospital in patients infected with the SARS-CoV-2 virus (https://ibn.fm/j0F22). Although COVID-19 is considered a respiratory disease that mainly affects patients’ pulmonary systems, research is increasingly documenting that the disease can affect many other organs and systems, including the brain. Since the start of the pandemic, it has been observed in a clinical setting that… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Sleep Apnea, Genetic Predisposition Linked to Severe Coronavirus Infection

July 16, 2021 13:06:11

A recent study conducted by researchers from the Academy of Finland has found that almost half of all coronavirus patients who also suffer from obstructive sleep apnea need to be hospitalized. The study, which was reported in the BMJ journals, noted that moderate to acute sleep apnea predisposes individuals to acute coronavirus. Other coronavirus risk factors include older age, diabetes and a high body mass index.

The researchers used FinnGen data for their study, which was backed by the Center of Excellence in Complex Disease Genetics. The researchers linked data obtained from the Finland National Infectious Disease Register on coronavirus diagnosis with…

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Stands Distinct in Precision Medicine

July 16, 2021 12:50:41

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development and individualizing patient treatment. “While others must wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine,” a recent article reads. “Predictive Oncology presently has the clinical information, including tumor drug response data and an in-house bioinformatics AI platform.” POAI has an impressive portfolio, spanning four different subsidiaries — Helomics, TumorGenesis, Soluble Biotech, and Skyline Medical — and including a list of assets that rivals the best operators in the space. “This strong portfolio makes POAI a strong standout in precision medicine, where precisely targeting drugs on the genomic profile of the patient’s tumor has become the aspiration for cancer therapy.”

To view the full article, visit https://ibn.fm/BebF1

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics, and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical, and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins, and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Brings Powerful Capabilities to Modern Clinical Trials

July 16, 2021 11:02:50

RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics. These provide next-generation capabilities that allow for more control of variables within a clinical setting, which is especially significant in modern cannabis clinical trials. While historical emphasis has largely been centered on potential harmful effects, today’s research teams are exploring the use of cannabis to address a wide range of chronic conditions, while it holds significant potential for pain relief. The future of cannabis study with the addition of dose-measuring devises looks promising, and RYAH is front-and-center on the trend. “RYAH has begun to work with an international oncology clinic in the UK on one of the largest clinical trials of its kind. The company will be studying the safety and efficacy of cannabis and hemp for the treatment of chronic pain,” reads a recent article. “Recently the company successfully shipped 10,000 dry-herb cartridges and QR codes in its initial shipment for the clinic’s pilot run. The complete order includes potentially thousands of RYAH Smart inhalers and millions of proprietary cartridges for the use of this study over the next five years.”

To view the full article, visit https://ibn.fm/gjPn1

About RYAH Group Inc.

RYAH is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries, pharmaceutical companies, and licensed processors (“LPs”) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle. For more information about the company, please visit www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Premieres New Clubhouse Show Titled ‘Activate Your Superhuman Mind’

July 15, 2021

July 15, 2021 13:55:57

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, announced that its new weekly talk show is scheduled to premiere on Clubhouse, a new type of social network based on voice. The increasingly popular channel enables millions of people around the world to gather to talk, listen and learn from each other in real time. The talk show, titled “Activate Your Superhuman Mind,” will cover a range of topics focused on achieving superior mental focus and energy. A new episode will be broadcast every Thursday, from 7:30–8:30 p.m. ET. The most recent episode, called “The Secret Science of the Integrated Entrepreneur,” discusses the role great mental power and agility plays in success at work as well as with family and health. The show is hosted by well-known TikTok star Danielle Haden and Dr. James Rouse, a trained naturopathic doctor, entrepreneur, bestselling author, speaker and athlete. “Our new Clubhouse show will bring to light the knowledge and experience of over 20 years of studies involving the human brain and its limitless potential,” said Healthy Extracts President Duke Pitts in the press release. “The show also represents one of several new initiatives we’ve launched to elevate consumer awareness of these topics and how they are addressed with our natural brands.”

To view the show, visit https://ibn.fm/48cF7

To view the full press release, visit https://ibn.fm/r5Qtf

About Healthy Extracts Inc.

“Live Life Young Again”

Healthy Extracts is a platform for developing or acquiring science-forward, clinically proven, plant-based and proprietary products in select high-growth categories within the multibillion-dollar nutraceuticals market. The company’s subsidiaries, BergametNA(TM) and Ultimate Brain Nutrients(TM) (“UBN”), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement containing Citrus Bergamot SuperFruit(TM). This superfruit is known to have the highest quality and concentration of polyphenols and flavonoids. Bergamet North America is backed by 17 clinical studies. UBN’s KETONOMICS(R) proprietary formulations have been clinically shown to improve brain health, including memory, cognition, focus and neuro-energy. UBN is pursuing intellectual property license opportunities for monetizing its IP portfolio that includes multiple issued and pending patents. For more information, visit: HealthyExtractsInc.com, BergametNA.com or TryUBN.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Report Finds That Use of Remote Health Has Grown Significantly

July 15, 2021

July 15, 2021 12:09:59

A recent survey conducted in the second quarter of this year by Parks Associates has found that more than one-half of broadband households own an internet-enabled fitness or health device that records biometric data, with another two-thirds revealing that they have undergone remote health consultation. The survey, which involved 5,000 broadband households in the United States was conducted by Parks Associates, a market research and consulting firm that specializes in emerging consumer technology products.

Parks Associates senior analyst Kristen Hanich stated that the overall familiarity with telehealth had assisted in driving the connected health device market. Hanich noted that there was a strong link between wanting the benefits of connected health, such as remote monitoring and…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Completion of Antiviral Drug Molecular Characterization Study

July 15, 2021

July 15, 2021 12:02:27

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced the results of its antiviral drug molecular characterization study. Lexaria worked with the National Research Council (“NRC”), Canada’s premier federally funded research organization, to conduct the study. Results from the NRC confirm the study objectives, including demonstrating that the company’s proprietary DehydraTECH(TM) processing and formulation technology does not create a covalently bonded new molecular entity (“NME”). In addition, the study confirmed that each of the five drugs tested remained stable without undergoing any change in chemical structure. The five drugs included remdesivir, ebastine, bepridil, rupintrivir and colchicine. The company noted that these findings are strongly supportive of accelerated regulatory filings through the Food and Drug Administration (“FDA”) and other international regulators with the end goal of an accelerated market authorization process. The company anticipates pursuing collaboration opportunities with other pharmaceutical industry partners to incorporate its exclusive technology in other ways.

To view the full press release, visit https://ibn.fm/WQY3G

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 20 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioScience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific Inc. (BRSF) Announces Merger Agreement With Piezo Motion to Expand Market Reach Into Fast-Growing Multi-Billion-Dollar Markets

July 14, 2021

July 14, 2021 13:19:41

BRSF is about to enter into a merger agreement to acquire Piezo Motion, a leading piezo motor technology developer
Piezo Motion’s technology will be deployed to leverage massive amounts of data that can be analyzed by artificial intelligence to assist medical professionals and researchers in recommending adequate precision treatments
Merger expected to expand markets for both companies and their potential to deliver innovative technologies to high-growth segments

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has announced that it has entered into a definitive merger agreement to acquire Piezo Motion Corp., a leading innovator of high-precision piezoelectric motion technology (https://ibn.fm/WBhls). By combining aspects of physical and social sciences with machine learning, the two companies seek to better understand and address emerging commercial demands in the market. Once completed, the merger is expected to expand the market footprint both for Brain Scientific and Piezo Motion and their potential to deliver innovative technologies to high-growth markets. The two companies leverage teams of scientists, engineers, and executives with a track record of developing and commercializing disruptive technologies. Brain Scientific’s two FDA-cleared products and commercialized devices, NeuroCap(TM) and NeuroEEG(TM) are designed to… Read More>> NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Further Research in Psychedelic Treatment for Mental Health

July 14, 2021

July 14, 2021 10:16:00

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has partnered with Ehave Inc., a provider of digital therapeutics for the psychedelic and mental health sectors. The partnership is intended to change the fact that although there are currently 250 identified biochemical markers about a broad range of the body’s organic system and how they function, the approach to utilize them to improve diagnostic accuracy and patient outcomes remains challenging for psychiatric disorders. Additionally, experts caution that even though a potential breakthrough has been found pertaining to treating a range of mental illnesses, which could have profound implications for a space that has seen few pharmacological advancements over recent decades, more research is needed. “This is where the partnership between Brain Scientific and Ehave can potentially make a difference,” reads a recent article. “The two companies signed the MoU defining a collaboration framework that will allow them to exploit graph-based AI linked data protocols to develop neural net algorithms.” The collaborators will use the data and algorithms to “statistically correlate biomarkers for the identification of psychedelic drug administration as a treatment for neurological disorders such as chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD, and schizophrenia.”

To view the full article, visit https://ibn.fm/vggxi

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers May Have Found Way to Retain Bladder After Bladder Cancer Diagnosis

July 14, 2021

July 14, 2021 09:05:26

Cancer metastasis is every patient and doctor’s nightmare when it comes to treating this deadly disease. Chemotherapy is usually the primary treatment option, with doctors following up with surgeries to remove any tumors. However, patients suffering from muscle-invasive bladder cancer have to make a life-altering decision to either undergo chemotherapy and have their bladder removed to reduce chances of the cancer recurring or take their chances with the cancer metastasizing and leave their bladder intact while undergoing chemotherapy.

Cystectomy, which refers to the surgical removal of the bladder, is the standard treatment plan for individuals who suffer from muscle-invasive bladder cancer. This happens when cancer cells grow into the bladder wall’s deeper layers, which makes it easier for the cells to spread beyond the bladder. Nearly one in every four people with this type of cancer are diagnosed at this stage. Researchers note…

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Covid-ID Lab Filling Existing Market Gap

July 13, 2021

July 13, 2021 12:19:59

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently announced that its distribution, storage and logistics partner, Max Pharma GmbH, began selling and delivering its 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”) in Germany on May 25. The company is likely to benefit from the country’s regulatory requirements and the government’s initiative that qualifies every resident to at least one free COVID-19 test per week. “Covid-ID Lab combines the accuracy of a PCR test, the gold standard for diagnosis, with the speed of an antigen test, thereby filling the existing market gap between centralized, automated PCR systems and disposable antigen tests,” reads a recent article. “It achieves this despite requiring less laboratory equipment and expertise. Notably, the high accuracy may well make XPhyto’s rapid test kit the go-to product on the market, increasing its demand.”

To view the full article, visit https://ibn.fm/BWffH

About XPhyto Therapeutics Corp.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Promising Study Results for Game-Changing Technology

July 13, 2021

July 13, 2021 10:50:42

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, today announced results from a national study it commissioned to asses patients’ airway function and obstructive sleep apnea (“OSA”) symptoms after undergoing the Vivos treatment. The study found that 28% of the 74 adult patients treated with the company’s FDA Class 1 DNA appliance for certain orofacial anomalies reported no remaining OSA symptoms, defined as patients having an Apnea Hypopnea Index (“AHI”) score of less than five post-treatment. “We are not aware of any treatment for OSA where 28% of patients are restored post-treatment to AHI scores that are within normal limits and with the potential for no ongoing intervention. In a previous outside analysis of real-world data, which is pending publication, the number of patients who finished Vivos treatment with fully resolved OSA was one out of three,” said Vivos chairman and CEO Kirk Huntsman. “In that instance, patients were treated directly for their OSA by the company’s FDA cleared mRNA appliance, which is very similar to the DNA appliance, showing our latest data is consistent. Simply put, we believe this clinical data shows that our core technology is a game-changer for OSA sufferers who undergo the Vivos treatment. As we recently reported, 97% of patients reported they fully achieved their treatment goals. The dentists who treated these patients know this is a huge breakthrough, and pretty soon the rest of the world will too.”

To view the full press release, visit https://ibn.fm/y8ZzT

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in over 17,000 patients worldwide by more than 1,200 dentists. Combining technologies and protocols that alter the size, shape, and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for Home Sleep Testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Study Explores Debilitating Childhood Brain Cancer Treatment Options

July 13, 2021

July 13, 2021 09:16:05

A recent study by the St. Jude Children’s Research Hospital and the School of Medicine at the Washington University in St. Louis proposes that young patients with an average risk medulloblastoma can, after a six-week radiation treatment regimen, undergo a radiation boost to a smaller area of the brain.

Medulloblastoma is a pediatric brain cancer that usually affects the spine and/or brain and can spread through a patient’s spinal fluid. The standard of care for this type of cancer includes radiation therapy to the whole spine and brain, after which an extra…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Marks Major Milestone for its Rapid Point-Of-Care Diagnostic Business Strategy

July 12, 2021

July 12, 2021 12:57:48

XPhyto began delivery of approximately 1,000 Covid-ID Lab test kits in Berlin
This marks a significant achievement commercially, as well as for the company’s point-of-care diagnostic business strategy
The lab tests are designed to offer reliable Covid-19 test results in under 25 minutes
XPhyto plans to capitalize on the rapid test market, projected to reach $39.1 billion by 2023

For the week starting June 27, 2021, XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) began delivery of approximately 1,000 Covid-ID Lab test kits to 10 different test centers in Berlin, Germany. This move is a major commercial achievement for the company and a significant milestone for its rapid point-of-care (“POC”) diagnostic business strategy. XPhyto describes Covid-ID Lab as a “25-minute testing revolution” (https://ibn.fm/4erIO). It is specifically designed to offer reliable Covid-19 test results in under 25 minutes while offering various other benefits, including eliminating unnecessary quarantine restrictions. With this test, XPhyto also promises to increase… Read More>> NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Cognitive Problems in Childhood Could Trigger Mental Health Issues Later in Life

July 12, 2021

July 12, 2021 11:52:42

New research conducted by a group of scientists from Finland and the UK, led by a team from University of Birmingham, has found that children who experience cognitive difficulties such as a lack of inhibition, poor memory or low attention may suffer from mental health problems as young adults or teenagers.

On a global scale, mental disorders affect about 10% of adolescents and children, with researchers finding that 75% of the disorders diagnosed in adulthood usually begin during adolescence or childhood. For instance, disorders such as psychosis, depression and bipolar disorder often emerge…

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Fast Track Designation for Lead Investigational Drug

July 12, 2021

July 12, 2021 09:39:01

CNS Pharmaceuticals’ (NASDAQ: CNSP) lead investigational drug, Berubicin, has been granted fast track designation by the U.S. Food and Drug Administration (“FDA”). That announcement came from WPD Pharmaceuticals Inc.(CSE: WBIO) (FSE: 8SV1), a clinical-stage pharmaceutical company that licenses Berubicin from CNSP. Berubicin is designed for the treatment of patients with recurrent glioblastoma multiforme (“GBM”). According to the announcement, fast track designation allows the company to interact more frequently with the FDA for the purposes of expediting the development and review process; the designation is reserved for drugs with the potential to address unmet medical need in the treatment of serious or life-threatening conditions. According to WPD, GBM is one of the most aggressive and deadly types of brain cancer, and many patients have almost no meaningful treatment options. The fast track designation creates an accelerated pathway for CNS Pharmaceuticals to gain approval for Berubicin, a move that offers significant potential benefits for WPD because the company has the rights to produce and sell the drug candidate in 29 countries, primarily in Europe. Most recently, CNSP began enrolling patients in its upcoming study of Berubicin.

To view the full press release, visit https://ibn.fm/x3JyC

About CNS Pharmaceuticals Inc.

Additionally, CNS Pharmaceuticals is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500 times more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain, pancreatic and ovarian cancers as well as lymphomas. For more information about the company, please visit www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

MSK Oncologists Share Approaches to Raise Survival Rates Among Soft Tissue Sarcoma Sufferers

July 9, 2021

July 9, 2021 13:05:18

Research has shown that nearly 50% of patients suffering from soft tissue sarcoma develop lung tumors. Presently, pulmonary metastasectomy, which is the surgical removal of lung tumors, is the primary treatment option for the disease as effective systemic treatments for metastatic soft tissue sarcoma are scarce. Despite this, guidelines for performing a pulmonary metastasectomy for soft tissue sarcoma don’t exist. and decisions to carry out the surgery are usually made on a person-to-person basis.

During the 96th annual American Association for Thoracic Surgery meeting, scientists from the Memorial Sloan Kettering Cancer Center gave a presentation on prognostic factors and survival data of more than 500 patients with pulmonary metastases from soft tissue sarcoma who had undergone…

NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Subsidiaries Showcase Products, Services at BIO Digital

July 9, 2021

July 9, 2021 10:12:48

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, participated in the second leg of the Biotechnology Innovation Organization (“BIO”) Digital, a premier international biotech partnering event held virtually on June 10-11 and 14-18, 2021, through its three subsidiaries. “While informative, the thrust of attending for companies like that of Predictive Oncology is networking and one-on-one sessions that can result in new partnerships or customers,” reads a recent article. “‘In previous conferences, Soluble Biotech has typically received more than a dozen requests for proposals, leading to new contracts for their main service of providing protein therapeutic formulations (i.e., formulations for vaccines, antibodies, virus-like particles),’ said Predictive Oncology CEO J. Melville Engle. He added that the Helomics unit is leveraging BIO’s one-on-one sessions to showcase its precision medicine discovery platform branded ‘PeDAL’… The conference allowed TumorGenesis to market its products and services specialized on culturing cancer cells from ovarian and breast cancers that more accurately mimic a patient’s tumors.”

To view the full article, visit https://ibn.fm/dZ5uo

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in William Blair Biotech Focus Conference

July 9, 2021

July 9, 2021 09:21:19

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be part of this year’s online William Blair Biotech Focus Conference. VTGN management will participate in a panel discussion titled “Updates in Neuropsych.” Key executives will also be available for one-on-one meetings throughout the virtual conference, which will be held July 15. The panel discussion is slated to begin at 9 a.m. PT. In the announcement, VTGN noted that the panel would be held virtually and that a live webcast would be accessible on the company’s website on the News/Events page.

To view the panel discussion, visit https://ibn.fm/Zf1Vy

To view the full press release, visit https://ibn.fm/RFVSI

About VistaGen Therapeutics Inc.

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Healthy Extracts Inc. (HYEX) Announces Ultimate Brain Nutrients ACTIVATE, a Breakthrough Nutraceutical Formulation

July 8, 2021

July 8, 2021 11:50:52

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of science-forward, clinically proven, plant-based products for heart and brain health, has unveiled a game-changing nutraceutical formulation: Ultimate Brain Nutrients ACTIVATE(TM) (“UBN”). According to the company, clinical studies indicate that the proprietary formulation naturally increases key brain activity by as much as 46%. Other results from studies show that ACTIVATE significantly improves human cognitive behavior and mental focus by activating areas of the brain that are key in attention, memory, mood and quick reaction times. HYEX has devoted more than two decades in research on the formulation, which included approximately 100 clinical studies on the key ingredients. ACTIVATE is based on the company’s proprietary, naturally derived Fuel4Thought(R) formulation, which contains no sugar and caffeine. The announcement noted that ACTIVATE is targeting the growing brain health supplements market, which has been forecast to grow at an 8% compounded annual growth rate (“CAGR”), reaching $13.4 billion by 2028. The formulation also leverages the growing niche market for nootropics, which are noted for their abilities to improve memory, creativity and motivation. According to the announcement, the nootropics market totaled $2.4 billion in 2020, with expectations to $6.3 billion by 2028. “UBN ACTIVATE represents the next evolution in mental energy and cognition by delivering the ultimate in brain food like no other product on the market today,” said Healthy Extracts president Duke Pitts in the press release. “Aside from its unique clinically proven formulation, it contains no processed sugar, which is the worst thing you can feed your brain. Instead, its naturally sourced ingredients are exactly what your brain needs for optimum functioning and health. . . . This new product also reflects our commitment to building a high-value portfolio of clinically proven, naturally formulated nutraceuticals that address huge market opportunities driven by increasing consumer demand. It is just the beginning of several new products planned for launch later this year, first in the U.S. and then globally.”

To view the full press release, visit https://ibn.fm/ei9f6

About Healthy Extracts Inc.

Healthy Extracts through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”), is engaged in proprietary research and development of natural plant-based formulations, as well as sales and distribution of natural-ingredient cardiovascular and neuro products. For more information about the company, please visit www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.f m/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Brings Cutting-Edge Tech to the Neurology Market

July 8, 2021

July 8, 2021 10:06:34

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has developed cutting-edge tech that bridges the widening gap in access to quality care. The company’s clinical-grade neurological devices, NeuroCap(TM) and NeuroEEG(TM), are portable, cost-efficient, easy-to-use, and allow for long-term monitoring. This technology will be part of a ketamine clinical study conducted by Ehave Inc. (OTC: EHVVF) to establish the statistical correlation between ketamine treatment and patient improvement. “Using BRSF’s technology, Ehave will be able to brain map the volunteer patients and show changes in the neuroplasticity of the areas impacted,” reads a recent article. “BRSF’s technology is ideal for clinical studies because of the company’s AI-assisted diagnostic analysis that increases the efficiency, consistency and accuracy of the data collected. Ehave is the newest to join the quickly expanding list of clinical studies that have taken advantage of BRSF’s next-generation technological solutions for the neurology market.”

To view the full article, visit https://ibn.fm/feZf8

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Telehealth and Its Usefulness Beyond the Coronavirus Pandemic

July 8, 2021

July 8, 2021 09:05:25

The coronavirus pandemic forced many physicians to switch from in-person visits to telehealth in a bid to keep their patients safe and also prevent the virus from spreading. While this may have been a temporary solution for some, many herald it as the future, with one industry expert urging optometrists to continue utilizing the technology for their practices even as in-person visits resume.

Christopher Wolfe recently gave a presentation at Vision Expo East in which he explained how at the onset of the coronavirus pandemic, instructions were given to not offer emergent or urgent care via telemedicine, revealing that in his practice, physical work hours were limited to 8 a.m. through 2 p.m. Now, he observed, telehealth allows physicians…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. (CSE: RYAH) are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Unveils Study Data Showing 97% of Vivos Patients Report Reaching Desired Outcome

July 7, 2021 12:42:49

Vivos Therapeutics (NASDAQ: VVOS) has released data from an independent patient survey related to its proprietary Vivos treatment for dental tissue anomalies and dentofacial malformations associated with obstructive sleep apnea (“OSA”) and other debilitating health conditions. The study reported that approximately 97% of patients surveyed said that they had achieved their desired outcome from the Vivos treatment for their OSA. Other study results show that 63% of patients reported that they depend on their dentist’s advice as they look for lasting solutions that addresses the root cause of their OSA and 29% indicated they searched for nonsurgical alternatives to current standards of care for treating OSA. Vivos is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate OSA. “Patients are the ultimate arbiter of whether a particular treatment modality has achieved its desired results,” said Vivos chair and CEO Kirk Huntsman in the press release. “This survey reaffirms that patients are in dire need of a solution for their OSA — one that is nonsurgical, noninvasive, nonpharmaceutical and low-cost — and that’s exactly the market niche that the Vivos treatment fills. The fact that nearly all patients surveyed reported that they had achieved their desired treatment outcome is a powerful testimony about their clinical and cosmetic results. Our technology just works.”

To view the full press release, visit https://ibn.fm/X0WA9

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves a customized oral appliance and protocols called the Vivos System. Vivos believes that its Vivos System oral appliance technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos also sells orthodontic appliances for adults and children. Vivos’ oral appliances have proven effective in more than 17,000 patients worldwide by more than 1,200 dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and may significantly reduce symptoms and conditions associated with mild-to-moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes VivosScore, powered by the SleepImage diagnostic technology for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology Inc. (NASDAQ: POAI) Companies Build New Labs, Expand Services for New Drug Discoveries

July 7, 2021 12:21:33

Two of Predictive Oncology’s four subsidiaries are constructing new Good Manufacturing Practices laboratories to offer additional services to customers
With its new GMP lab, Soluble Biotech will provide customers formulations that can go directly to clinical trials, as well as manufacture proprietary media used in its chromatography kits
TumorGenesis will use its GMP lab to produce its proprietary media that tricks tumor cells into growing outside the body the same as inside the body in addition to producing proteins and other biological products used in diagnosing, treating, and modifying tumor cells

On the heels of raising $21.34 million and three of its companies participating in the popular Biotechnology Innovation Organization (“BIO”) conference, Predictive Oncology (NASDAQ: POAI) continued its busy month with more substantive developments from its subsidiaries. The Minneapolis-based company, which develops and offers a suite of products and services across its portfolio companies focused on drug development and targeted cancer treatments, announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new GMP (good manufacturing practices) laboratories (https://ibn.fm/UWoLK). From its facilities in Birmingham, Alabama, Soluble Biotech specializes in formulation solutions and stability services used for vaccines, monoclonal antibodies, and biologics. The GMP facility ramps up these… Read More>> NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Key Board Appointment of Mary L. Rotunno

July 7, 2021 12:17:52

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Mary L. Rotunno, J.D. to its board of directors. “Mary brings to our team more than 30 years of leadership experience, which began with serving patients as a registered nurse and transitioned to serving clients in health care law, both allowing her to pursue her steadfast commitment to helping others and advancing the future of mental health and wellness,” said VistaGen CEO Shawn Singh. “Her extensive track record as an advocate for both patients and health care providers is unique and will provide deep and valuable insights into strategies for value-based care and an understanding of the entire life cycle of the mental health care experience. Mary has also served as a trusted advisor on complex governance, regulatory and compliance requirements for several companies. Her strategic vision, skill for scenario planning, and enterprise risk management expertise will be key in the next phases of our corporate development as we continue to pursue our core mission — to improve mental health and well-being for individuals in the U.S. and abroad.”

To view the full press release, visit https://ibn.fm/Ab6Jz

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Collaboration with the University of Michigan

July 7, 2021 09:10:41

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced an agreement with the University of Michigan to perform research related to Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. According to the update, the collaboration is part of a series of upcoming bridging studies designed to expand Tryp’s intellectual property portfolio for the company’s novel TRP-8803 drug formulation compared with conventional oral formulations of synthetic psilocybin. The studies will also facilitate the advancement of TRP-8803 into Phase 2b clinical trials. “We are excited to initiate our collaboration with the University of Michigan with critical research supporting the unique properties of our proprietary psilocybin formulation and method of delivery,” said Jim Gilligan, Ph.D., president and chief science officer of Tryp Therapeutics. “The University of Michigan has extensive expertise in the dosing and delivery of active pharmaceutical ingredients and world-class expertise in several pain related indications that are aligned with our interests. We expect this to be the first of many opportunities for collaboration with this prestigious academic institution.”

To view the full press release, visit https://ibn.fm/XTYBq

About Tryp Therapeutics Inc.

Tryp Therapeutics is a pharmaceutical company focused on developing compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain chronic pain and eating disorder indications. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than 5 million people in the United States. The company is also preparing to initiate a Phase 2a clinical study for eating disorders in partnership with Jennifer Miller, M.D. at the University of Florida. For more information about the company, visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

New Blood Test Could Speed Up Diagnosis of Brain Cancer

July 7, 2021 08:48:49

A study conducted at the University of Strathclyde, in collaboration with clinicians from the Walton NHS Foundation Trust, the University of Liverpool and the Western General Hospital, has helped design a blood test that speeds up brain cancer diagnosis. This patented technology uses infrared light to produce a blood sample’s biosignature then utilizes artificial intelligence to check for any signs of cancer.

The technology, which was reported in the “Nature Communications” journal, is being commercialized…

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

The Coronavirus Pandemic Has Adversely Affected Genitourinary Cancer Patients

July 6, 2021

July 6, 2021 12:07:25

The findings of an initial virtual survey that was presented at the 2021 Genitourinary Cancers Symposium demonstrate that the coronavirus pandemic had a negative influence on patients who suffer from genitourinary malignancies. Genitourinary cancers are mainly found in the male reproductive system and the urinary system. These cancers include adrenal cancer, testicular cancer, urethral cancer, bladder cancer, kidney cancer, prostate cancer and cancers of the penis.

The preliminary survey highlights that as a result of the pandemic, almost 12% of study participants missed at least one dose of a prescribed medication, 12% avoided making the trip to a pharmacy to receive required medication, and roughly 17% reported that they avoided or delayed seeking medical care. Another 26% reported…

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers Find That Early Childhood Cancer Discovery May Prevent Metastasis

July 2, 2021 14:41:31

Researchers have made a new discovery in a fatal and aggressive childhood cancer known as Ewing sarcoma, which could possibly help hinder the spread of cancer cells. This new discovery offers new insights into what causes the process that enables cancer cells to survive as they travel through the bloodstream of an individual, spreading beyond the primary tumor site.

Scientists with BC Cancer and the University of British Columbia have discovered that this particular type of cancer cells develop a shield that protects them from the bloodstream’s harsh environment…

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Predictive Oncology Inc. (NASDAQ: POAI) Stands Strong as Innovator, Leader in Precision Medicine

July 2, 2021 12:20:35

Company plans to use proceeds from direct offering for business development, drug repurposing and discovery and expansion of its laboratory facilities
POAI portfolio spans four different subsidiaries, including list of assets rivaling best operators in the space
Predictive Oncology is strong standout in precision medicine

Predictive Oncology (NASDAQ: POAI) has closed on its registered direct offering (https://ibn.fm/9buhx).The offering, which totaled $21.34 million, will be a boon for the knowledge-driven company as it continues its focus on applying artificial intelligence (“AI”) to personalized medicine and drug discovery. Operating in the AI space, the company is looking at almost vast potential as it focuses efforts on personalized medicine and drug discovery. The POAI portfolio is impressive, spanning four different subsidiaries… Read More>> NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Bringing Researchers Next-Level Tools for Hard-to-Treat Diseases

July 2, 2021 09:42:03

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is looking to give oncology drug developers an upper hand, thereby increasing the chances of the drugs’ success from the onset. “Raising the success rate for experimental cancer drugs starts in the laboratory, where leading-edge technology could be instrumental in providing prescient insights that ultimately result in better clinical outcomes,” reads a recent article. TumorGenesis, a subsidiary of POAI, has partnered with Swedish cell culture system company Cellevate AB. “The collaboration will involve using TumorGenesis’ expertise in cancer cell culture growth in combination with Cellevate’s specialty in the emerging field of nanofiber matrixes. The initial indication for the partners is ovarian cancer.” The goal is to bring researchers the next level of tools for hard-to-treat diseases, helping them avoid early mistakes that contribute to the already exorbitant cost of drug development. “The partnership provides new opportunities for both companies. It further represents an expansion of the Predictive Oncology product portfolio into an area it hadn’t addressed before.”

To view the full article, visit https://ibn.fm/oOU5z

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Pediatric NeuroCap Is First-of-its-Kind for Pediatric Market

July 2, 2021 09:26:46

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is bringing to market new technology that allows EEG testing to be deployed rapidly and accurately in children and adolescents. The Pediatric NeuroCap is intended to solve significant barriers limiting EEG monitoring in pediatric care. “Instead of improvising to make adult-size EEG electrodes fit pediatric patients’ smaller head circumference, Brain Scientific fully adapted its revolutionary NeuroCap to be used in children,” reads a recent article. “The Pediatric NeuroCap comes in two sizes and includes 22 integrated, pre-gelled electrodes compliant with the 10-20 international system. With the Pediatric NeuroCap, the logistical struggle to perform EEG testing in pediatric patients appears on its way to be solved — the testing can be conducted within five minutes by any member of the clinical team. The Pediatric NeuroCap is positioned to be the first disposable and pre-gelled headset available for the pediatric market, bringing faster, more efficient and sanitary brain diagnostics to the pediatric setting.”

To view the full article, visit https://ibn.fm/3eBxB

About Brain Scientific Inc.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Finalizing Design of Innovative Cancer Visualization Technology

July 1, 2021 13:56:37

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design of its i/Blue Imaging System(TM), with manufacturing expected to be completed in 2022. The system is an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. It solves challenges associated with using blue and white light cystoscopies, which require surgeons to switch back and forth between images and rely on memory to resect. “The company’s advanced technology will show both images simultaneously side-by-side on one screen, providing surgeons with better visualization to remove the cancer and making procedures more efficient,” reads a recent article. The American Cancer Society anticipates that new cases of bladder cancer in the United States will reach 83,730 in 2021, with deaths reaching 17,200. Further, approximately 50% of patients who have had minimally invasive surgery to remove non-muscle-invasive bladder cancer will see their cancer return. Imagin’s innovative system is intended to “potentially help lower this high recurrence rate.”

To view the full article, visit https://ibn.fm/KF7vv

About Imagin Medical

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Study Finds Adding Choline Nutrient to Diet May Help Combat Alzheimer’s

July 1, 2021 12:56:02

A study conducted by researchers from the Arizona State University found that a long-term choline dietary regimen could possibly prevent Alzheimer’s disease. Choline is a nutrient that can be used as a dietary supplement and is found in some foods.

Ramon Velazquez, the study’s lead author, and his fellow researchers at the university’s Neurodegenerative Disease Research Center, investigated whether choline could reduce Alzheimer’s effects. The study, which was carried out in 2019, discovered transgenerational benefits of Alzheimer’s disease-like symptoms in mice whose mothers…

NOTE TO INVESTORS: The latest news and updates relating to Healthy Extracts Inc. (OTCQB: HYEX) are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Business Update, Progress on Driving Berubicin’s Development

July 1, 2021 11:57:32

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update. Among the highlights, the company reported on its continued progress to drive Berubicin towards commercialization for the treatment of glioblastoma multiforme (“GBM”). “In the last 60 days alone, we have achieved fundamental clinical, regulatory and corporate milestones that together demonstrate CNS’ operational, strategic and financial strengths. We are continuously de-risking our Berubicin clinical program by driving development of this truly novel treatment forward as expeditiously as possible. In a mere 18 months from our IPO, our laser focus on this program created a potentially pivotal study now open for enrollment with patient dosing expected to commence at any time. With the addition of our recent Fast Track Designation for GBM, we believe we are poised to execute on our milestones ahead and bring a meaningful treatment to patients who suffer from this devasting and heretofore incurable disease,” said John Climaco, CEO of CNS Pharmaceuticals. “Additionally, the $4.7 million of ATM transactions significantly bolsters our cash runway and provides funding to advance our important clinical programs for several quarters to come. We are passionate about driving Berubicin’s development forward, creating value in the near- and long-term, and, most importantly, making a positive impact on patients’ lives.”

To view the full press release, visit https://ibn.fm/DFGMZ

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Vivos Therapeutics Inc.’s (NASDAQ: VVOS) Strides in Treatment Innovation Highlighted in New Book

July 1, 2021 11:39:31

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, has been a trailblazer in diagnosing and treating mild-to-moderate obstructive sleep apnea (“OSA”). Years of research have culminated in its main product, the Vivos System, which has been instrumental in treating OSA among adults. In his new book, Pneumopedics and Craniofacial Epigenetics, Vivos Therapeutic’s founder and Chief Medical Officer Dr. G. Dave Singh shares the process behind Vivos System’s innovation and the scientific and biological foundation of the product. “Dr. Singh’s primary goal with this book is to spread the word far and wide about the technology, how it can help people think about health conditions such as OSA, and how such ailments are treated going forward. He covers craniofacial growth along with developmental genetics,” reads a recent article. “By doing so, he addresses the link between dentofacial anomalies and developmental deficiencies that are associated with downstream conditions including, but not limited to OSA. Dr. Singh also cements the scientific and biological foundation upon which Vivos Therapeutics’ proprietary approach rests. By so doing, he sheds more light on OSA while offering some incredible insights into the future of mild-to-moderate OSA diagnosis and treatment.”

To view the full article, visit https://ibn.fm/Gemlv

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in over 17,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Advance Psychedelic Medicine Program